The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 8 May 2026•Updated 9 May 2026•

1 min read

Biotech Firms Face Nasdaq Delisting Pressures as Rockwell Medical Joins Warning List

Key Facts

1Aditxt received a delisting notice from Nasdaq because its share price remained below $1 for 30 consecutive business days.

2The company is ineligible for a 180-day grace period due to cumulative reverse stock splits exceeding a 250-to-1 ratio within two years.

26 days ago

Version History

Version 126 days ago

What changed: Updated the story to include Rockwell Medical (RMTI), which is now facing similar Nasdaq delisting risks, noting it has been granted a 180-day grace period.

Compliance pressures on Nasdaq are mounting as Rockwell Medical (RMTI) recently received a formal notice for failing to maintain the minimum $1.00 bid price for 30 consecutive business days. Unlike Aditxt, which faced immediate delisting due to excessive previous splits, Rockwell Medical has been granted a 180-day grace period until November 4, 2026, to regain compliance. The company intends to propose a reverse stock split in its 2026 proxy statement as a potential strategic solution to maintain its listing status. This development follows the ongoing struggles of Aditxt, highlighting a broader trend of financial instability among small-cap biotech firms. Investors remain cautious as these companies navigate regulatory hurdles and seek to restore market confidence through structural adjustments.